SBFM: sunshinebiopharma.com Price/Earnings to Growth Multiple
Sunshine Biopharma is currently undergoing a forced R&D restructuring to preserve liquidity. The comparison of P/E and growth rates visualizes this pivot, where 0.00 reflects the baseline level of the metric. Stability is provided by the development of RNA therapies for gastrointestinal cancer in collaboration with industry behemoths, while strict adherence to climate standards during drug delivery ensures the preservation of their properties.
Metric breakdowns and analytics for Sunshine Biopharma, Inc. (SBFM)
- share price and consensus valuation forecast:
- market capitalization information:
- book value of equity indicators:
- business debt structure and liquidity details:
Debt to Capital Sunshine Biopharma|SBFM - Long-Term Debt to Equity|Short-Term Debt to Capital Coefficient Sunshine Biopharma Inc.|SBFM - Company Total Debt|Debts to Book Capitalization Sunshine Biopharma|SBFM - Company Long-Term Debt|Company Short-Term Indebtedness Sunshine Biopharma|Interim Coverage Ratio sunshinebiopharma.com
- company profitability and valuation multiples indicators:
SBFM - Net Profit|Expected Net Income Sunshine Biopharma|SBFM - P/E Multiple|Market Cap to Projected Earnings sunshinebiopharma.com|SBFM - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Sunshine Biopharma|SBFM - Operating profit EBITDA|Net earnings per one share for the last twelve months Sunshine Biopharma|SBFM - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months sunshinebiopharma.com|SBFM - Earnings growth in current year|Net earnings per share growth forecast for next year Sunshine Biopharma
Summary company analytics:SBFM sunshinebiopharma.com
Investors assess an asset's margin of safety through the ratio of market value to earnings growth rates, where a value below one signals that the business is undervalued. Given the colossal expenditures of Sunshine Biopharma (SBFM) on clinical trials for oncology drugs, the PEG ratio allows for a determination of whether earnings dynamics justify the current venture capital risks for this asset class.
Competitors of Sunshine Biopharma
ONC (BeiGene Ltd.) - Growth-Adjusted Payback Ratio|PEG Multiple HALO (Halozyme Inc.)|RVMD - Price/Earnings to Growth Multiple|AAPG: Price/Earnings to Growth Multiple|CGON - PEG Multiple|UroGen Pharma (URGN) - Price/Earnings to Growth Ratio|Bicara Therapeutics Inc - Growth-Adjusted Payback Ratio|PSNL (Personalis Corp) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Erasca Oncology ERAS|Price/Earnings to Growth Ratio Delcath Systems, Inc. (DCTH)|Growth-Adjusted Market Cap to Net Income ymabs.com|Aura Biosciences - Price/Earnings to Growth Multiple|PEG Multiple Candel Therapeutics Inc. CADL|ARAY - Price/Earnings to Growth Ratio|SLS (SELLAS Life Sciences) - Growth-Adjusted P/E Ratio|Actuate Therapeutics, Inc. (ACTU) - Price/Earnings to Growth Ratio|CTOR - Growth-Adjusted Market Cap to Net Income|HURA (TuHURA Biosciences Inc.) - PEG Multiple|TARA: Growth-Adjusted Payback Ratio|PEG Multiple FATE|Growth-Adjusted Market Cap to Net Income aadibio.com|Price/Earnings to Growth Ratio TScan Therapeutics, Inc. TCRX|CSBR: Growth-Adjusted P/E Ratio|XBiotech USA - PEG Multiple|Price to Earnings Adjusted for Growth Rate CEL-SCI Corporation|OSTX (OS Therapies Inc) - Price/Earnings to Growth Multiple|Radiopharm Theranostics Ltd - Growth-Adjusted Payback Ratio|ARTV (Artiva Biotherapeutics Inc.) - PEG Multiple|Price/Earnings to Growth Ratio ANL|PEG Multiple VERU|Growth-Adjusted Market Cap to Net Income Tempest Therapeutics Inc|Price/Earnings to Growth Ratio Xilio Therapeutics XLO|Renovaro Biosciences (RENB) - Price to Earnings Adjusted for Growth Rate|MURA - Price/Earnings to Growth Ratio|Market Cap to Earnings and Growth Ratio KAPA|OKUR: PEG Multiple|CytoMed Therapeutics Limited - Growth-Adjusted Payback Ratio|CRIS (Curis Inc.) - PEG Multiple|PEG Multiple Apollomics Corp|Price/Earnings to Growth Ratio Tharimmune, Inc. (THAR)|ADVB (advanbiomed.com) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Genprex GNPX|CLDI - Price/Earnings to Growth Multiple|Xenetic Bio - PEG Multiple|SLRX - PEG Multiple|Purple Biotech (PPBT) - Price/Earnings to Growth Ratio|AONC - Growth-Adjusted Market Cap to Net Income|BGNE (BeiGene) - PEG Multiple|Price/Earnings to Growth Ratio CKPT|PEG Multiple ELEV|ICAD: Market Cap to Earnings and Growth Ratio|Price/Earnings to Growth Ratio Ikena Oncology IKNA|NTBL - Price/Earnings to Growth Multiple|Viracta - PEG Multiple|MorphoSys Inc (MOR) - Price/Earnings to Growth Multiple|NAYA: PEG Multiple|Ascentage (AAPGV) - PEG Multiple
